Health Care Slips Amid Cyclical Bias -- Health Care Roundup

Health-care companies fell as traders rotated into more economically sensitive sectors.

Revance shares plunged after the Food and Drug Administration rejected its application for its DAXI treatment for frown lines, but the drug still has its believers on Wall Street.

The Food and Drug Administration approved Boehringer Ingelheim's Cyltezo as a "biosimilar" generic version of AbbVie's blockbuster Humira, the world's biggest-selling drug, used to treat diseases from rheumatoid arthritis to gut disorders.

Write to Rob Curran at [e-mail]

(END) Dow Jones Newswires

10-18-21 1710ET